AB1130 CAUSAL ASSOCIATION BETWEEN LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND PSORIATIC ARTHRITIS
Q. Dong,X. Yang,M. Zhu,J. Y. Chen,Q. Feng,Q. Yu,P. F. He,X. Li,S. X. Zhang
DOI: https://doi.org/10.1136/annrheumdis-2023-eular.3406
IF: 27.973
2023-01-01
Annals of the Rheumatic Diseases
Abstract:Background Psoriatic arthritis (PsA) is an inflammatory disease that causes inflammation and swelling of the joints and entheses in addition to skin symptoms(PsA)[1]. Chronic psoriatic lesions may increase serum concentrations of low-density lipoprotein cholesterol (LDL-C) by producing large amounts of IL-6 and other pro-inflammatory cytokines, which release free fatty acids, cholesterol, and triglycerides from the adipose tissue[2]. However, whether LDL-C affects articular psoriasis is unclear. Objectives We used a two-sample Mendelian randomization (MR) analysis to investigate the causal associations of LDL-C with PsA. Methods Firstly, we obtained LDL-C-associated single-nucleotide polymorphisms (SNPs) from a GWAS published by the UK Biobank, including up to disequilibrium (LD) threshold for clumping was set to r2 < 0.001. The clumping window size was set to 10000 kb, and we selected autosomal biallelic SNPs with P-values < 5 × 10-8. Thirdly, as for MR analyses, F statistics were calculated to evaluate the strength of each instrument, the F-statistic of each SNP> 10, indicating a low risk of weak instrument bias. Inverse variance weighted (IVW) was the primary method to assess the association of genetically predicted LDL-C and PsA risk. Fourthly, MR-Egger and weighted median were applied to validate the results from IVW. The Cochrane Q test and funnel plots were used to test the possible heterogeneity. The directional pleiotropy was separated by intercepting from MR-Egger and MR-presso. Finally, a leave-one-out sensitivity analysis was also performed. Results With 158 LDL-C-associated SNPs, LDL-C was a hazard factor for PsA(OR =1.30,95%CI 1.02-1.65, P=0.032), which was consistent in direction with the weighted median(OR=1.38,95%CI,1.00-1.91, P=0.050) and MR-Egger(MR-Egger: OR=1.43, 95%CI 1.01-2.04, P=0.045). Heterogeneity existed in the results(P<0.05). But IVW could provide a robust causal estimate in the presence of heterogeneity[3]. No evidence of pleiotropy was observed (MR-Egger-intercept: -0.0049, P=0.447), and leave-one-out sensitivity analysis showed that removing any SNP would not change the overall result, suggesting this finding was available. Details of the results were shown in Figure 1. Conclusion LDL-C was a hazard factor for PsA. Monitoring and lowering serum concentrations of LDL-C may make a difference in psoriasis treatment and slow down the process of PsA. References [1]Skornicki, Michelle et al. “Clinical Burden of Concomitant Joint Disease in Psoriasis: A US-Linked Claims and Electronic Health Records Database Analysis.” Advances in therapy vol. 38,5 (2021): 2458-2471. doi:10.1007/s12325-021-01698-7 [2]Pietrzak, Aldona et al. “Serum concentration of interleukin 6 is related to inflammation and dyslipidemia in patients with psoriasis.” Postepy dermatologii i alergologii vol. 37,1 (2020): 41-45. doi:10.5114/ada.2018.78028 [3]Chen, Lu et al. “No causal effect of tea consumption on cardiovascular diseases: A two-sample Mendelian randomization study.” Frontiers in cardiovascular medicine vol. 9 870972. 7 Sep. 2022, doi:10.3389/fcvm.2022.870972 Acknowledgements: NIL. Disclosure of Interests None Declared.